With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

In this article, we are going to take a look at where The Mosaic Company (NYSE:MOS) stands against other firms that dominated Monday upsurge. Ten companies—predominantly in the healthcare sector ...

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

Hunter syndrome results from the absence of an enzyme needed to break down cellular waste. Without it, waste builds up in the body, causing progressive damage to various systems.

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with Hunter ...

The issue has also sparked discussion of a phenomenon known as Kessler syndrome. Kessler syndrome is a hypothetical scenario proposed by NASA scientist Donald J. Kessler in 1978, predicting what ...

From medicine to transport and communications, there were many examples of artificial intelligence (AI) being used in new sectors or to improve people’s lives last year. In Italy, the city of ...